appConfigEntityId

bodyType

customContents

entityId

entityUuid

isVideo

articlePageQuery

article

articleSchemaContent

content

hooksArticlePageAdvertisementConfigArticle

hooksArticlePageFloatingButtonConfigArticle

appConfig

filter

json

liveArticle

Kenny Shui

Arthur Tsang

Amid the global coronavirus pandemic, vaccine development is a race against time in which we all have a stake.
The development time for vaccines from bench to bedside is normally 10 to 15 years. Yet, with the great effort of scientists all over the world, multiple Covid-19 vaccines were developed within one to two years.
As reported recently, the Oxford-AstraZeneca vaccine, in particular, has probably saved more lives than any other, with nearly 2.5 billion doses administered, more than any other vaccine, two-thirds of which have gone to low- and lower-middle-income countries.
First approved for use by British regulators in December 2020, the vaccine was developed in less than a year. As the unsung heroes behind the vaccine said, strong execution and concurrent administration of vaccine development procedures were key levers.

On prototyping the vaccine, animal tests in mice and non-human primates were conducted concurrently. Meanwhile, Phase I trials had already been planned and manufacturing for the pilot batches of vaccines for human trials was under way during preclinical studies.
British regulators fast-tracked the clinical trial approval process and the trials kicked off the day after successful preclinical results were obtained. The global multicentre Phase II and III trials held afterwards were combined as well. Under normal circumstances, all these steps would be separated for detailed data analyses.
In contrast, a team from the University of Hong Kong, including government adviser Professor Yuen Kwok-yung, encountered lots of obstacles to producing a vaccine. The team successfully prototyped an intranasal vaccine for Covid-19 in early 2020, yet Phase I trials were not completed until July last year. Commercialisation of the vaccine is expected to take another two to three years.
The team had a good head start by leveraging its research into a vaccine for seasonal influenza, which began about four years ago. In March 2020, it received funding for preclinical testing as well as support for clinical trials later.
However, as there is no vaccine plant in town, the team turned to plants in mainland China. It took rather a long time to find an appropriate one and the process was further delayed by the unclear approval mechanism for the exportation of home-grown vaccine seeds into the mainland.

The lengthy approval time for Phase I clinical trials is another issue. Such trials are currently approved by the Pharmacy and Poisons Board, whose scale is hardly comparable to regulatory bodies like the US Food and Drug Administration and the Chinese National Medical Products Administration.
Given the lack of regulatory professionals in Hong Kong – that is, those who have knowledge of drug administration processes, such as clinical trials and approval standards and mechanisms – approval for Phase I clinical trials here generally take about half a year. This is longer than in rival markets. Notably in Australia, approval takes only about one month.
Following the completion of Phase I trials, the team is now preparing for Phase II and III trials on a larger scale. As the later-phase trials involve far more human subjects, cooperating with mainland hospitals will be a viable model. However, Hong Kong has limited experience in leading multicentre trials while enabling pioneering mainland-Hong Kong cooperation will surely be demanding.
Financing is another critical issue in carrying out later-phase trials, which usually cost hundreds of millions of Hong Kong dollars. Most of our current Covid-19 vaccines were developed by pharmaceutical companies, some in partnership with universities, and many receive financial support from the government.


However, our home-grown vaccine has always been a university-led project: seed funding for preclinical studies was provided by the Coalition for Epidemic Preparedness Innovations, a philanthropic international organisation, and the Phase I clinical trials were co-funded by the coalition, alongside the Hong Kong government.
Public funding amounted to around HK$20 million, which is significantly less than the HK$43 million (US$5.51 million) provided by the coalition. Stronger government support is clearly needed for this university-led project.
The absence of large pharmaceutical companies in Hong Kong and a lack of private funding for vaccine development reveal the city’s incomplete biotechnology ecosystem.
‘More reforms needed’ to attract biotech firms to list in Hong Kong
A strong invention with a potentially large market has the makings of a high-value product, yet the lack of supporting facilities and smooth market access to mainland China impede the commercialisation of technological breakthroughs. The government needs to streamline the biotechnology development process by completing the supply chain.
The government should also establish a high-level science and development office comprised of scientists to advise the cabinet on technology development issues, including the formulation of a biotechnology development blueprint, complete with financing strategies.

Furthermore, the approval time for Phase I clinical trials should be shortened by scaling up the regulatory body and avoiding repetitive examinations.
Meanwhile, the Shenzhen-Hong Kong innovation and technology cooperation zone that spans the border can be a springboard for mainland-Hong Kong cooperation.
Not only should small-scale vaccine plants be built to fulfil demand for pilot-batch pharmaceutical products, the zone should also allow the movement of biomaterials across the border for research and development, and act as a platform for Hong Kong clinicians to import best practices for clinical trials into mainland China and lead multicentre later-phase clinical trials in both Hong Kong and mainland hospitals.
Clearly, the British moon-shot task of launching a vaccine within a year is not a matter of luck but was built on preceding efforts in creating an accommodating biotechnology ecosystem. Hong Kong should not miss out on further opportunities but, rather, act with speed and determination to realise its vision.
Kenny Shui is assistant research director and head of economic development at Our Hong Kong Foundation, where Arthur Tsang is an assistant researcher in tech innovation


Fauci refuses to answer questions at heated US Senate hearing on Covid-19 origins

2 infants in Hong Kong confirmed severely infected with Covid-19 just days apart

First AI-designed ‘universal vaccine’ tested in humans

Scientists test universal vaccine for cold, flu, Covid and allergies

Coronavirus vaccine

Tale of two vaccines: AstraZeneca’s road to success offers lessons for Hong Kong’s biotech ambitions

A nurse prepares a booster dose of the Oxford-AstraZeneca Covid-19 vaccine during a vaccination drive for people over 60, in Mexicali, Mexico, on January 3. Fast-tracked regulatory approval and the ability to run clinical trials concurrently helped ensure the vaccine was developed for use within a year. Photo: Reuters

Mexican Red Cross paramedics receive booster shots of the Oxford-AstraZeneca Covid-19 vaccine, in Ciudad Juarez, Mexico, on January 6. Nearly 2.5 billion doses of the AstraZeneca vaccine had been administered worldwide, as of December 14, more than any other Covid-19 vaccine. Photo: Reuters

Hong Kong microbiologist Yuen Kwok-yung speaks at a press conference on May 29 last year. Professor Yuen is part of an HKU team developing a nasal spray Covid-19 vaccine. Photo: Xiaomei 

Hong Kong’s Lok Ma Chau Loop has been earmarked for development of the Shenzhen-Hong Kong innovation and technology cooperation zone. Photo: Martin Chan

Covid-19 experts agree: 2021 was a failure for vaccine distribution

Illustration: Brian Wang

AstraZeneca to make ‘modest profit’ from coronavirus vaccine, but not from developing countries

A woman receives an AstraZeneca vaccine. The firm will now start to take a ‘modest profit’ from its coronavirus vaccine as it moves away from the non-profit model it has operated so far but says profits will not be made from developing countries. Photo: AP

Coronavirus: Hong Kong researchers get HK$100 million in grants to look into origins of Covid-19, effectiveness of additional vaccine doses

Hong Kong researchers have been granted HK$100 million for studies focusing on the coronavirus. Photo: EPA-EFE

David Hui Shu-cheong, Stanley Ho Professor of Respiratory Medicine at CU Medicine; attends a press conference on a Global Study Led by CU Medicine and HKUMed Discovers a Hepatitis C Virus Drug as Potent Treatment for COVID-19 in Prince of Wales Hospital, Sha Tin. 04MAY21 SCMP/ Winson Wong

People queue up to have their vaccine jabs (Fosun Pharma / BioTech vaccine)  at Sun Yat Sen Memorial Park Sports Centre in Sai Ying Pun. 19JUN21 SCMP/ Xiaomei Chen

Opinion

Coronavirus

Analysis & Opinion

An HKU team was one of the first to come up with a potential vaccine, but its bumpy development process makes one thing clear: Hong Kong has the talent but not the ecosystem to bring biotechnological breakthroughs to market


An HKU team was one of the first to come up with a potential vaccine, but its bumpy development process makes one thing clear: Hong Kong has the talent but not the ecosystem to bring biotechnological breakthroughs to market.


Coronavirus Hong Kong

Coronavirus pandemic

Coronavirus pandemic: All stories

Disease

Medicine

Hong Kong

Expresses the views, ideas and conclusions of the author. (Eg. Enough of Crazy Rich Asians, think of crazy poor Hongkongers.)
